Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysisNicholas A. Vitanza, Julie R. Park, Adam Johnson et al.|Nature Medicine|2021Cited by 319
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from GermanyPeter Bader, Andrea Jarisch, Hermann Einsele et al.|Blood Advances|2023Cited by 57
First-in-human comparison of second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastomaNavin Pinto, Julie R. Park, Annette Künkele et al.|Research Square|2024Cited by 4
The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed NeuroblastomaNavin Pinto, Julie R. Park, Annette Künkele et al.|Clinical Cancer Research|2026Cited by 0